Acticor Biotech Aktie
| 0,17EUR | -0,11EUR | -39,29% |
WKN DE: A3C6GM / ISIN: FR0014005OJ5
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Afer - Flore | 0,95 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 14 | 18 | 25 | 21 | 28 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
Bilanz (in Mio. EUR) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 14 | 10 | 17 | 12 | 9 |
| Summe Anlagevermögen | 1 | 1 | 1 | 1 | 0 |
| Summe Aktiva | 15 | 11 | 18 | 13 | 10 |
Bilanz (in Mio. EUR) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 6 | 9 | 7 | 15 | 15 |
| Summe Eigenkapital | 9 | 2 | 11 | -2 | -5 |
| Summe Passiva | 15 | 11 | 18 | 13 | 10 |
Adresse
| Wojo Building, 75014 Paris | |
| Telefon | +33 (7) 76-23-38-13 |
| Internet | http://www.acticor-biotech.com |
Management
|
Adeline Meilhoc
Head-Global Clinical Development |
|
Alain H. Munoz
Chairman |
|
Alain Parthoens
Director |
|
Andrea Comenducci
Senior Director-Medical |
|
Anouar Sari
Head-Clinical Operations |
|
Antoine Lebel
Communication Assistant |
|
Aymeric Humblot
Head-Finance & Administration |
|
Catherine Boule
Director |
|
Elsa Sirou
Senior Manager-Regulatory Affairs |
|
Francois Guillet
Chief Financial Officer |
|
Gilles Avenard
Chief Executive Officer & Director |
|
Guy Heynen
Director |
|
Hervé Bachelot Lallier
Director |
|
James Stearns
Observer |
|
Jean-Pierre Cazenave
Independent Director |
|
Jessica Jami
Manager-Regulatory Affairs |
|
Leila Nicolas
Director |
|
Patricia Zilliox
Independent Director |
|
Philippe Billiald
Scientific Founder |
|
Rinaldo del Bono
Director |
|
Sirine Bougamra
Medical Director |
|
Sophie Binay
General Manager & Chief Scientific Officer |
|
Yannick Plétan
Chief Medical Officer & General Manager |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
